A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

Journal of Infectious Diseases

Volumn 183, Issue 10, 2001, Pages 1485-1493

  Evans, Thomas G ^a   Bonnez, William ^a   Rose, Robert C ^a,b   Koenig, Scott ^c   Demeter, Lisa ^a,b   Suzich, JoAnn A ^c   O’Brien, Diane ^a   Campbell, Meredith ^a   White, Wendy I ^c   Balsley, James ^c   Reichman, Richard C ^a,b  

^a Infectious Diseases Unit   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ADULT; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE CALCULATION; DRUG TOLERABILITY; FEMALE; HELPER CELL; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VACCINATION; VIRUS PARTICLE; VIRUS RECOMBINANT; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELLS, CULTURED; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MALE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; SPECIES SPECIFICITY; T-LYMPHOCYTES; VACCINES, DNA; VIRAL VACCINES;

EID: 0035873682     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320190     Document Type: Article

References (55)

1. Papillomavirus infections: A major cause of human cancers
2. Papillomaviruses
3. Therapeutic approaches to papillomavirus infections
4. Diseases due to human papillomavirus (sexually transmitted)
5. Heterosexual relationships and condom-use in the spread of sexually transmitted diseases to women
6. The epidemiology of cervical carcinogenesis
7. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP)
8. Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response
9. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera
10. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts
11. Serum IgG, gM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups
12. Papillomavirus-like particles
13. Identification of human papillomavirus seroconversions
14. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men
15. Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection
16. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
17. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
18. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
19. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
20. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles
21. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles
22. In vitro HPV-II infection of human foreskin
23. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line
24. In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata
25. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients
26. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers: The AIDS Vaccine Evaluation Group
27. Immunological study of condylomata acuminata in men infected with the human immunodeficiency virus
28. Immunological events in regressing genital warts
29. Association of HIV and STDs in Haiti: Implications for blood banks and HIV vaccine trials
30. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women
31. T-cell responses to human papillomavirs in cervical dysplasia
32. Lymphoproliferative responses to human papillomaviruses in patients with cutaneous warts
33. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts
34. Humoral and cellular immunity to papillomavirus in patients with cervical dysplasia
35. A sequence pattern common to T cell epitopes
36. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: Identification of T cell determinants, HLA-DR restriction and virus type specificity
37. Definition of murine T helper cell determinants in the major capsid protein of human papillomavirus type 16
38. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles
39. T cell epitopes in human papilloma virus proteins
40. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia
41. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls
42. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia
43. T-cell proliferative response to human papillomavirus type 16 peptides: Relationship to cervical intraepithelial neoplasia
44. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study
45. Biology of human TH1 and TH2 cells
46. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles
47. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology
48. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children
49. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls
50. Induction of bystander T cell proliferation by viruses and type I interferon in vivo
51. Stimulation of naive and memory T cells by cytokines
52. Virus-like particles induce MHC class I-restricted T-cell responses: Lessons learned from the hepatitis B small surface antigen
53. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis
54. Condylomata acuminata and risk of cancer: An epidemiological study
55. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11